Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD). Methods The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, ...
OBJECTIVES: Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy characterized by the ass...
Objectives: This study aims to establish the first national treatment recommendations by the Turkish...
International audienceOBJECTIVES: To develop recommendations about treatment (except anti-TNF agents...
Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatme...
Background Since the publication of the European League Against Rheumatism recommendations for the p...
Objective To update the European League Against Rheumatism (EULAR) recommendations for the pharmacol...
Background: Since the publication of the European League Against Rheumatism recommendations for the ...
Objective To update the European League Against Rheumatism (EULAR) recommendations for the pharmacol...
The aims of treatment for psoriatic arthritis (PsA) are to control inflammation, normalise functions...
International audienceObjectives: To develop recommendations about treatment (except anti-TNF agents...
Recent advances in the therapeutics of psoriatic arthritis (PsA) have provided more options to clini...
Objective To update the 2011 Italian Society of Rheumatology (SIR) recommendations for the use of bi...
OBJECTIVES: Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy characterized by the ass...
Objectives: This study aims to establish the first national treatment recommendations by the Turkish...
International audienceOBJECTIVES: To develop recommendations about treatment (except anti-TNF agents...
Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatme...
Background Since the publication of the European League Against Rheumatism recommendations for the p...
Objective To update the European League Against Rheumatism (EULAR) recommendations for the pharmacol...
Background: Since the publication of the European League Against Rheumatism recommendations for the ...
Objective To update the European League Against Rheumatism (EULAR) recommendations for the pharmacol...
The aims of treatment for psoriatic arthritis (PsA) are to control inflammation, normalise functions...
International audienceObjectives: To develop recommendations about treatment (except anti-TNF agents...
Recent advances in the therapeutics of psoriatic arthritis (PsA) have provided more options to clini...
Objective To update the 2011 Italian Society of Rheumatology (SIR) recommendations for the use of bi...
OBJECTIVES: Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy characterized by the ass...
Objectives: This study aims to establish the first national treatment recommendations by the Turkish...
International audienceOBJECTIVES: To develop recommendations about treatment (except anti-TNF agents...